I think a better way to put it is Vertex will continue to dominate the HCV market when it becomes clear that the PSI-7977/RBV cure rate for HCV GT1 is inferior to Incivek/interferon/RBV. It will be difficult to justify using an oral regimen with an inferior cure rate in these patients when the cost of treatment failure is so high. The 79 percent vs. 66 percent cure rate for Incivek vs. Victrelis has resulted in a 70 percent market share for Incivek. This occurred despite an earlier approval for Victrelis and the marketing power and political power of Merck. Without an effective PSI-7977 oral regimen for HCV GT1 patients, Pharmasset is no better off than so many other pharma companies with as yet unproven oral regimens for HCV GT1 in early stages of clinical trials. In fact, one of the most promising oral regimens for this patient population is the phase II study by Vertex of Incivek/VX222/RBV with data expected early in 2012.
still dont trust FDA/politicans meaning your very own congress,senators who have privy to what will pass and what wont.These people are in contact with FDA.Get it FEDERAL,this is how they make their millions and its not against the law! for us like Martha Stewart we go to prison.Do you think for one moment this part of the Goverment is honest?I dont think so,sorry but its as crooked as my dogs back leg!!!! Too much money involved it will pass regardless of soc or anything else that why wall street has made VRUS its golden boy.
I agree the FDA may approve Pharmasset's oral regimen for patients intolerant of interferon, regarless of genotype. The problem will be getting the docs who prescribe these meds to favor an expensive oral regimen with a lower cure rate over Incivek/interferon/RBV. There is a lot of talk about an oral HCV regimen being the "Holy Grail" of HCV treatment but what really matters is if you can cure the patient.